PT2880053T - Mitigação de fibrose e danos de tecidos por anticorpo antiltbp4 - Google Patents

Mitigação de fibrose e danos de tecidos por anticorpo antiltbp4

Info

Publication number: PT2880053T
Authority: PT; Portugal
Prior art keywords: ltbp4; growth factor; binding protein; tissue damage; transforming growth
Prior art date: 2012-08-01

Application number

PT138352430T

Other languages

English (en)

Original Assignee

Ikaika Therapeutics Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-08-01

Filing date

2013-08-01

Publication date

2020-05-22

2013-08-01 Application filed by Ikaika Therapeutics Llc filed Critical Ikaika Therapeutics Llc

2020-05-22 Publication of PT2880053T publication Critical patent/PT2880053T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Mycology (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PT138352430T 2012-08-01 2013-08-01 Mitigação de fibrose e danos de tecidos por anticorpo antiltbp4 PT2880053T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201261678564P	2012-08-01	2012-08-01

Publications (1)

Publication Number	Publication Date
PT2880053T true PT2880053T (pt)	2020-05-22

Family

ID=50025687

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT138352430T PT2880053T (pt)	2012-08-01	2013-08-01	Mitigação de fibrose e danos de tecidos por anticorpo antiltbp4

Country Status (15)

Country	Link
US (10)	US9873739B2 (pt)
EP (2)	EP3711771A1 (pt)
AU (6)	AU2013313282B2 (pt)
CA (1)	CA2880649C (pt)
CY (1)	CY1123029T1 (pt)
DK (1)	DK2880053T3 (pt)
ES (1)	ES2791778T3 (pt)
HK (1)	HK1211307A1 (pt)
HR (1)	HRP20200818T1 (pt)
HU (1)	HUE049217T2 (pt)
PL (1)	PL2880053T3 (pt)
PT (1)	PT2880053T (pt)
RS (1)	RS60318B1 (pt)
SI (1)	SI2880053T1 (pt)
WO (1)	WO2014039189A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY186389A (en) *	2014-05-13	2021-07-22	Univ Pennsylvania	Compositions comprising aav expressing dual antibody constructs and uses thereof
WO2016054155A1 (en) *	2014-09-30	2016-04-07	Primegen Biotech, Llc.	Treatment of fibrosis using deep tissue heating and stem cell therapy
KR20160101692A (ko)	2015-02-17	2016-08-25	한국전자통신연구원	다채널 신호 처리 방법 및 상기 방법을 수행하는 다채널 신호 처리 장치
US11535665B2 (en)	2015-05-13	2022-12-27	The Trustees Of The University Of Pennsylvania	AAV-mediated expression of anti-influenza antibodies and methods of use thereof
IL268644B1 (en)	2017-02-28	2025-02-01	Univ Pennsylvania	Adeno-associated virus group F vector and uses for it
TW201837170A (zh)	2017-02-28	2018-10-16	賓州大學委員會	新穎ａａｖ媒介的流感疫苗
JOP20190200A1 (ar)	2017-02-28	2019-08-27	Univ Pennsylvania	تركيبات نافعة في معالجة ضمور العضل النخاعي
EA202190416A1 (ru)	2018-08-02	2021-06-23	Дайн Терапьютикс, Инк.	Мышечно-специфические комлексы и их применение для лечения плече-лопаточно-лицевой мышечной дистрофии
CN113347990A (zh) *	2018-12-21	2021-09-03	西北大学	膜联蛋白在预防和治疗肌膜损伤中的用途
WO2020139977A1 (en)	2018-12-26	2020-07-02	Northwestern University	Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
US11771776B2 (en)	2021-07-09	2023-10-03	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2024182358A1 (en) *	2023-02-27	2024-09-06	Dyne Therapeutics, Inc.	Methods and compositions for inhibiting progression of intramuscular fibrosis

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS6023084B2 (ja)	1979-07-11	1985-06-05	味の素株式会社	代用血液
US4640835A (en)	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en)	1985-06-19	1990-11-14	Ajinomoto Co., Inc.	Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en)	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
WO1990014837A1 (en)	1989-05-25	1990-12-13	Chiron Corporation	Adjuvant formulation comprising a submicron oil droplet emulsion
US5466468A (en)	1990-04-03	1995-11-14	Ciba-Geigy Corporation	Parenterally administrable liposome formulation comprising synthetic lipids
US5372807A (en)	1990-05-14	1994-12-13	University Of Medicine And Dentistry Of New Jersey	Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use
US5637459A (en)	1990-06-11	1997-06-10	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: chimeric selex
US5270163A (en)	1990-06-11	1993-12-14	University Research Corporation	Methods for identifying nucleic acid ligands
US5399363A (en)	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
DE69432815T2 (de)	1993-03-19	2003-12-11	The Johns Hopkins University School Of Medicine, Baltimore	Wachstumsfaktor-8
US5994618A (en)	1997-02-05	1999-11-30	Johns Hopkins University School Of Medicine	Growth differentiation factor-8 transgenic mice
US6891082B2 (en)	1997-08-01	2005-05-10	The Johns Hopkins University School Of Medicine	Transgenic non-human animals expressing a truncated activintype II receptor
US6369201B1 (en)	1998-02-19	2002-04-09	Metamorphix International, Inc.	Myostatin multimers
US6004937A (en)	1998-03-09	1999-12-21	Genetics Institute, Inc.	Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
NZ513642A (en)	1999-01-21	2004-02-27	Metamorphix Inc	Growth differentiation factor inhibitors and uses therefor
US6465493B1 (en)	1999-04-09	2002-10-15	Smithkline Beecham Corporation	Triarylimidazoles
EP1200119A2 (en)	1999-07-20	2002-05-02	Pharmexa A/S	Method for down-regulating gdf-8 activity
AU782925B2 (en)	2000-01-18	2005-09-08	Orico Limited	Myostatin and mimetics thereof
CO5271680A1 (es)	2000-02-21	2003-04-30	Smithkline Beecham Corp	Compuestos
GB0007405D0 (en)	2000-03-27	2000-05-17	Smithkline Beecham Corp	Compounds
EP1191097A1 (en)	2000-09-21	2002-03-27	Leids Universitair Medisch Centrum	Induction of exon skipping in eukaryotic cells
US20040039198A1 (en)	2000-11-16	2004-02-26	Bender Paul E.	Compounds
GB0102668D0 (en)	2001-02-02	2001-03-21	Glaxo Group Ltd	Compounds
TW200526779A (en)	2001-02-08	2005-08-16	Wyeth Corp	Modified and stabilized GDF propeptides and uses thereof
US7320789B2 (en)	2001-09-26	2008-01-22	Wyeth	Antibody inhibitors of GDF-8 and uses thereof
JP4429729B2 (ja)	2002-02-21	2010-03-10	ワイスエルエルシー	Ｇａｓｐ１；フォリスタチンドメイン含有タンパク質
PL374966A1 (en)	2002-02-21	2005-11-14	Wyeth	Follistatin domain containing proteins
US7572599B2 (en)	2002-09-16	2009-08-11	The Johns Hopkins University School Of Medicine	Metalloprotease activation of myostatin, and methods of modulating myostatin activity
US7261893B2 (en)	2002-10-22	2007-08-28	Wyeth	Neutralizing antibodies against GDF-8 and uses therefor
US20040223966A1 (en)	2002-10-25	2004-11-11	Wolfman Neil M.	ActRIIB fusion polypeptides and uses therefor
AR042545A1 (es)	2002-12-20	2005-06-22	Amgen Inc	Agentes ligantes que inhiben la miostatina
WO2004083241A2 (en)	2003-03-19	2004-09-30	Takeda Pharmaceutical Company Limited	Btc-interacting proteins and use thereof
EP1729793B1 (en)	2004-03-02	2015-07-22	Acceleron Pharma Inc.	Alk7 and myostatin inhibitors for muscle wasting disorders
BRPI0508716A (pt)	2004-03-23	2007-08-07	Lilly Co Eli	anticorpo monoclonal, processo para produzir o mesmo, composição farmacêutica, e, uso de um anticorpo monoclonal
SI1766010T1 (sl)	2004-06-28	2011-06-30	Univ Western Australia	Protismiselni oligonukleotidi za induciranje preskakovanja eksonov in postopki za njihovo uporabo
EP2314617B1 (en)	2004-07-23	2015-06-24	Acceleron Pharma Inc.	ActRII receptor polypeptides
US20060194845A1 (en)	2004-07-29	2006-08-31	Schering Corporation	Use of ALK 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals
PE20061395A1 (es)	2005-04-25	2007-01-15	Amgen Fremont Inc	Anticuerpos contra miostatina
CA2731216A1 (en) *	2008-07-18	2010-01-21	Oragenics, Inc.	Compositions for the detection and treatment of colorectal cancer
US8084601B2 (en)	2008-09-11	2011-12-27	Royal Holloway And Bedford New College Royal Holloway, University Of London	Oligomers
FR2943249B1 (fr)	2009-03-18	2011-08-12	Genethon	Utilisation de la decorine pour augmenter la masse musculaire
BRPI1011513A2 (pt)	2009-03-23	2016-03-22	Inst Medical W & E Hall	composto, composição, métodos para modular uma resposta imune, para tratar e/ou prevenir uma doença, para modular a captação e/ou a depuração de células, ou uma porção das mesmas, para modular o reconhecimento, processamento e/ou apresentação de antígeno de material derivado de células ou de uma porção das mesmas, para diagnosticar, prognosticar e/ou monitrar o estado de uma doença, para distinguir entre uma célula necrótica ou célula morta, para enriquecer células dendríticas, ou um subconjunto das mesmas ou precursor das mesmas, e para detectar uma célula, usos do composto e/ou da composição, de células dentríticas ou de precursor das mesmas e de um polipetídeo, de um composto e de uma composição, polinucleotídeo vetor, célula hospedeira, população, e, kit
JP5931720B2 (ja)	2009-05-08	2016-06-08	クルナ・インコーポレーテッド	Ｄｍｄファミリーに対する天然アンチセンス転写物の抑制によるジストロフィンファミリー関連疾患の治療
WO2012006181A2 (en)	2010-06-29	2012-01-12	Mount Sinai School Of Medicine	Compositions and methods for inhibiting oncogenic micrornas and treatment of cancer

2013
- 2013-08-01 PT PT138352430T patent/PT2880053T/pt unknown
- 2013-08-01 HU HUE13835243A patent/HUE049217T2/hu unknown
- 2013-08-01 PL PL13835243T patent/PL2880053T3/pl unknown
- 2013-08-01 ES ES13835243T patent/ES2791778T3/es active Active
- 2013-08-01 RS RS20200604A patent/RS60318B1/sr unknown
- 2013-08-01 US US13/957,100 patent/US9873739B2/en active Active
- 2013-08-01 EP EP20152849.4A patent/EP3711771A1/en active Pending
- 2013-08-01 SI SI201331718T patent/SI2880053T1/sl unknown
- 2013-08-01 AU AU2013313282A patent/AU2013313282B2/en active Active
- 2013-08-01 DK DK13835243.0T patent/DK2880053T3/da active
- 2013-08-01 CA CA2880649A patent/CA2880649C/en active Active
- 2013-08-01 EP EP13835243.0A patent/EP2880053B8/en active Active
- 2013-08-01 WO PCT/US2013/053255 patent/WO2014039189A1/en active Application Filing
2015
- 2015-12-09 HK HK15112163.9A patent/HK1211307A1/xx unknown
2017
- 2017-12-28 US US15/857,122 patent/US20180134785A1/en not_active Abandoned
2018
- 2018-01-04 AU AU2018200078A patent/AU2018200078A1/en not_active Abandoned
- 2018-09-05 US US16/122,333 patent/US20190002557A1/en not_active Abandoned
2019
- 2019-04-23 US US16/392,108 patent/US20190256589A1/en not_active Abandoned
- 2019-08-28 AU AU2019222850A patent/AU2019222850A1/en not_active Abandoned
- 2019-12-16 US US16/716,382 patent/US20200123247A1/en not_active Abandoned
2020
- 2020-05-20 HR HRP20200818TT patent/HRP20200818T1/hr unknown
- 2020-05-25 CY CY20201100496T patent/CY1123029T1/el unknown
- 2020-08-14 US US16/994,225 patent/US20200385457A1/en not_active Abandoned
2021
- 2021-02-08 AU AU2021200783A patent/AU2021200783B2/en active Active
- 2021-03-31 US US17/219,845 patent/US20210238274A1/en not_active Abandoned
- 2021-11-29 US US17/536,768 patent/US20220089717A1/en not_active Abandoned
2022
- 2022-07-07 US US17/811,233 patent/US20230235044A1/en not_active Abandoned
- 2022-11-15 AU AU2022271391A patent/AU2022271391A1/en not_active Abandoned
2024
- 2024-04-25 US US18/646,068 patent/US20240287171A1/en not_active Abandoned
- 2024-07-17 AU AU2024204925A patent/AU2024204925A1/en active Pending

Also Published As

Publication number	Publication date
US20200385457A1 (en)	2020-12-10
EP2880053A1 (en)	2015-06-10
RS60318B1 (sr)	2020-07-31
US20140037637A1 (en)	2014-02-06
WO2014039189A1 (en)	2014-03-13
HRP20200818T1 (hr)	2020-08-07
PL2880053T3 (pl)	2021-01-11
CA2880649C (en)	2023-03-14
US9873739B2 (en)	2018-01-23
AU2022271391A1 (en)	2022-12-15
AU2021200783B2 (en)	2022-10-06
US20180134785A1 (en)	2018-05-17
US20230235044A1 (en)	2023-07-27
US20240287171A1 (en)	2024-08-29
HK1211307A1 (en)	2016-05-20
EP2880053B8 (en)	2020-04-15
AU2021200783A1 (en)	2021-03-04
US20190256589A1 (en)	2019-08-22
AU2018200078A1 (en)	2018-01-25
AU2024204925A1 (en)	2024-08-08
EP3711771A1 (en)	2020-09-23
US20190002557A1 (en)	2019-01-03
AU2013313282A1 (en)	2015-02-26
ES2791778T3 (es)	2020-11-05
EP2880053A4 (en)	2016-03-09
SI2880053T1 (sl)	2020-08-31
HUE049217T2 (hu)	2020-09-28
US20210238274A1 (en)	2021-08-05
US20200123247A1 (en)	2020-04-23
AU2019222850A1 (en)	2019-09-19
CA2880649A1 (en)	2014-03-13
US20220089717A1 (en)	2022-03-24
CY1123029T1 (el)	2021-10-29
DK2880053T3 (da)	2020-05-11
EP2880053B1 (en)	2020-02-26
AU2013313282B2 (en)	2018-02-01

Publication	Publication Date	Title
HK1211307A1 (en)	2016-05-20	Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) (ltbp4)
HK1231361A1 (zh)	2017-12-22	視網膜假體
EP2579819A4 (en)	2013-12-11	IMPLANT COMPONENTS AND METHOD
RS62297B1 (sr)	2021-09-30	Prirodne kombinovane hormonske supstitucione formulacije i terapije
IL236358A0 (en)	2015-02-26	Combination formulas of natural hormone replacements and therapies
IL224338A (en)	2017-02-28	Surgical implant
EP2538988A4 (en)	2014-08-06	METHOD FOR TISSUE-DECELULARIZATION
EP2533772A4 (en)	2016-03-16	METHOD AND COMPOSITIONS FOR WOUND HEALING
PL2651462T3 (pl)	2021-07-26	Rozszerzalny implant oraz system implantu
EP2757999A4 (en)	2015-05-27	IMPLANT OF HARD FABRIC
GB201400072D0 (en)	2014-02-19	Implant and implant system
GB201006527D0 (en)	2010-06-02	Femoral implant
PL2621383T3 (pl)	2016-06-30	Dwustronny implant blaszki kręgu
IL225298A0 (en)	2013-06-27	Lamina grafting system
GB201005625D0 (en)	2010-05-19	Immunogenic proteins and compositions
GB201103423D0 (en)	2011-04-13	Immunogenic proteins and compositions
PL2552539T3 (pl)	2016-01-29	Wszczep siatkówkowy i proteza wzroku zawierająca taki wszczep
PT2619357T (pt)	2019-11-29	Relva artificial
IL240766A0 (en)	2015-10-29	Artificial bone molds and works for bone approximation
ZA201307790B (en)	2014-09-25	Prosthesis for connecting an anatomical duct
IL223095A0 (en)	2013-02-03	Methods and compositions for treatment nf-kb-mediated and a7 integrin-suppressed diseases
GB2478062B (en)	2014-12-10	Toner Compostions and methods
PL2568928T3 (pl)	2016-04-29	Implant chirurgiczny
AU2011900679A0 (en)	2011-03-10	Surgical Implant and Method
SG10201405762UA (en)	2014-11-27	Hair Restoration Surgery